Global PROteolysis Targeting Chimera (PROTAC) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global PROteolysis Targeting Chimera (PROTAC) Market Research Report 2024
A proteolysis targeting chimera (PROTAC) is a heterobifunctional small molecule composed of two active domains and a linker capable of removing specific unwanted proteins. Rather than acting as a conventional enzyme inhibitor, a PROTAC works by inducing selective intracellular proteolysis. PROTACs consist of two covalently linked protein-binding moleculesone capable of engaging an E3 ubiquitin ligase, and another that binds to a target protein meant for degradation. Recruitment of the E3 ligase to the target protein results in ubiquitination and subsequent degradation of the target protein by the proteasome. Because PROTACs need only to bind their targets with high selectivity (rather than inhibit the target protein's enzymatic activity), there are currently many efforts to retool previously ineffective inhibitor molecules as PROTACs for next-generation drugs.
According to Mr Accuracy reports’s new survey, global PROteolysis Targeting Chimera (PROTAC) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole PROteolysis Targeting Chimera (PROTAC) market research.
Key manufacturers engaged in the PROteolysis Targeting Chimera (PROTAC) industry include Arvinas, Kymera, C4 therapeutics, Captor therapeutics, Vividion, Cullgen, Pfizer, Merck and Genentech, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of PROteolysis Targeting Chimera (PROTAC) were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole PROteolysis Targeting Chimera (PROTAC) market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global PROteolysis Targeting Chimera (PROTAC) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Arvinas
Kymera
C4 therapeutics
Captor therapeutics
Vividion
Cullgen
Pfizer
Merck
Genentech
AstraZeneca
Amgen
Bayer
Segment by Type
ARV-110
ARV-471
KYM-001
Others
Oncology
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The PROteolysis Targeting Chimera (PROTAC) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global PROteolysis Targeting Chimera (PROTAC) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole PROteolysis Targeting Chimera (PROTAC) market research.
Key manufacturers engaged in the PROteolysis Targeting Chimera (PROTAC) industry include Arvinas, Kymera, C4 therapeutics, Captor therapeutics, Vividion, Cullgen, Pfizer, Merck and Genentech, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of PROteolysis Targeting Chimera (PROTAC) were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole PROteolysis Targeting Chimera (PROTAC) market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global PROteolysis Targeting Chimera (PROTAC) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Arvinas
Kymera
C4 therapeutics
Captor therapeutics
Vividion
Cullgen
Pfizer
Merck
Genentech
AstraZeneca
Amgen
Bayer
Segment by Type
ARV-110
ARV-471
KYM-001
Others
Segment by Application
Oncology
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The PROteolysis Targeting Chimera (PROTAC) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices